SEC Form 4/A · accession 0001437749-26-029228
Monopar Therapeutics · MNPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Raymond Anderson
Director
Period of report
Aug 25, 2026
Accepted (ET)
Aug 28, 2026 · 7:41 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001645469
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 25, 2026 | M | 1,402 | $30.00 | A | 6,775 | D | |
| Common Stock | Aug 25, 2026 | M | 1,740 | $30.00 | A | 8,515 | D | |
| Common StockF4 | Aug 25, 2026 | S | 694 | $110.04 | D | 7,821 | D | |
| Common StockF5 | Aug 25, 2026 | S | 646 | $111.07 | D | 7,175 | D | |
| Common StockF6 | Aug 25, 2026 | S | 1,802 | $113.05 | D | 5,373 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2 | $30.00 | Aug 25, 2026 | M | 1,402 | A | — | Sep 17, 2027 | Common Stock | 1,402 | 2,803 | D |
| Stock OptionF3 | $30.00 | Aug 25, 2026 | M | 1,740 | A | — | Aug 8, 2028 | Common Stock | 1,740 | 3,480 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.
- F2On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.
- F3On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
Remarks
On August 27, 2026, the reporting person filed a Form 4, which inadvertently omitted two option exercises that were made prior to the reporting person's sale of shares of common stock. Both the option exercises and the sales of common stock were effected pursuant to a Rule 10b5-1 Plan. The prior Form 4 also did not account for Monopar Therapeutics Inc.'s 5 to 1 reverse stock split of its common stock, which was effected August 12, 2024 (the "Reverse Stock Split"). The amount of securities reported on this amended Form 4 have been adjusted to reflect the Reverse Stock Split.